<?xml version="1.0" encoding="UTF-8"?>
<p id="Par100">By the recombinant expression of the S-protein, Novavax has developed and produced immunogenic virus-like Nanoparticles. It is at the preclinical stage and it is estimated that it will be available for the market 3 months after the announcement [
 <xref ref-type="bibr" rid="CR114">114</xref>].
</p>
